Page 27 - 76_01
P. 27
VOL. 76 (1), 59-84, 2010 METALOPROTEINASAS, MATRIZ EXTRACELULAR Y CÁNCER
12. Folgueras, A. R.; Pendas, A. M.; Sánchez, L. M. & López-Otín, C. (2004) Me-
talloproteinases in cancer: from new function to improved inhibition strate-
gies. Int. J. Dev. Biol. 48: 411-424.
13. Liotta, L. A.; Tryggvason, K.; Garbosa, S., Hart, I. et al. (1980) Metastatic
potential correlates with enzymatic degradation of basement membrane colla-
gen. Nature. 284: 67-68.
14. Deruyina, E. & Quigley, J. (2006) Matrix metalloproteinases and tumor metas-
tasis. Cancer Metastasis Rev. 25: 9-34.
15. Mochizuki, S. & Okada, Y. (2007) ADAMs in cancer cell proliferation and
progression. Cancer Sci. 98: 621-628.
16. Edwards, D. R.; Handsley, M. M. & Pennington, C. J. (2008) The ADAM me-
talloproteinases. Mol. Aspects Med. 29: 258-289.
17. Steiner, D. F. (1998) The proprotein convertases. Curr. Opin. Chem. Biol. 2:
31-39.
18. López-Otín, C. & Bond, J. S. (2008) Proteases: multifunctional enzymes in life
and disease. J. Biol. Chem. 283: 31433-31437.
19. López-Otín, C. & Matrisian, L. (2007) Emerging roles of proteases in tumor
progression. Nature Rev. Cancer. 7: 800-808.
20. Huang, S. C.; Sheu, B. C.; Chang, W. C.; Chaeg, C. Y.; Wang, P. H. & Lin, S.
(2009) Extracellular matrix proteases - Cytokine regulation role in cancer and
pregnancy. Front. Biosci. 14: 1571-1588.
21. Puente, X. S.; Sánchez, L. M.; Gutiérrez-Fernández, A.; Velasco, G. & López-
Otín, C. (2005) A genomic view of the complexity of mammalian proteolytic
systems. Biochem. Soc. Trans. 33: 331-334.
22. Nakamoto, T.; Yamagata, T., Sakai, T., et al. (2000) CIZ, a zinc finger protein
that interacts with p130(cas) and activates the expression of matrix metallo-
proteinases. Mol. Cell Biol. 20: 1649-1658.
23. Ye, S. (2000) Polymorphisms in matrix metalloproteinase gene promoters:
implications in regulation of gene expression and susceptibility of various
diseases. Matrix Biol 19: 623-629.
24. López-Otín, C. & Overall, C. M. (2002) Protease degradomics a new challenge
for proteomics. Nat. Rev. Mol. Cell Biol. 3: 509-519.
25. Coussens, L. M.; Fingleton, B. & Matrisian, L. M. (2002) Matrix metallopro-
tease inhibitors and cancer: trials and tribulations. Science. 295: 2387-2392.
26. Fingleton, B. (2003) Matriz metalloproteinases inhibitors for cancer thera-
py: the current situation and future prospects. Expert Opin. Ther. Targets. 7:
385-397.
27. Handsley, M. M. & Edwards, D. R. (2005) Metalloproteinases and their inhi-
bitors in tumor angiogenesis. Int. J. Cancer. 115: 849-860.
28. Fridman, R. (2006) Metalloproteinases and cancer. Cancer Metastasis Rev. 25:
7-8.
29. Hanahan, D. & Weinberg, R. (2000) The hallmark of cancer. Cell. 100: 57-70.
30. Bergers, G. & Benjamin, L. E. (2003) Tumorigenesis and the angiogenic
switch. Nat. Rev. Cancer. 3: 401-410.
83
